Sanofi-aventis stands behind the safety of Lantus®
Paris, France – June 26, 2009 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has just been made aware of data associated with a retrospective follow-up of four patient registries. The results of these data clearly show that no definitive conclusions can be drawn regarding a possible causal relationship between Lantus® (insulin glargine) use and the occurrence of malignancies, as the authors of the study point out. Clinical studies, which represent the gold standard of evidence, do not indicate an association between insulin glargine and cancer. “Given the extensive clinical evidence